Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta-Analysis
High-dose inactivated influenza vaccine (HD-IV) provides superior protection compared with SD-IV against P&I and all-cause hospitalisation in older adults, with the greatest benefits among younger seniors and those without cardiovascular disease.
Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults
A Cluster Randomized Crossover Study
Summary Report: IDC Stakeholder Community Meeting - 10 June 2026, Brussels
Key takeaways and next steps from the first in-person meeting of the IDC
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
mRNA-1010 was superior to standard-dose licensed vaccines for prevention of RT-PCR–confirmed, protocol-defined influenza-like illness in adults 50 years of age or older. (Article for subscribers)
News
Policy & Recommendations
The European Commission authorised the first combined COVID-19 and influenza vaccine for people 50 years and older
The EC has recently published on the Union Register of medicinal products the decision granting EU marketing authorisation for mCombriax, an mRNA vaccine to protect people aged 50 years and older against COVID-19 and seasonal influenza.
Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination
Previous studies, including large cohort analyses comparing vaccinated and unvaccinated adults, suggest that routine immunizations such as inactivated influenza vaccines (IIVs) may reduce Alzheimer dementia (AD) risk.
News
Policy & Recommendations
Improving vaccination coverage rates in adult populations: A handbook for health managers and policymakers
Older adults continue to face high risks from vaccine preventable diseases, yet coverage rates for influenza, pneumococcal disease and other respiratory infections remain suboptimal in many Member States.